Back to today’s briefing

Story perspectives

Study Reveals ADAR1's Key Role in Myeloma Treatment Resistance

4/15/2025

34 5

Summary

Story summary

A groundbreaking study in Blood reveals that ADAR1 plays a crucial role in lenalidomide resistance in multiple myeloma. Lowering ADAR1 levels could boost treatment sensitivity, paving the way for innovative therapies like CRBN E3 ligase modulators and ADAR1 inhibitors, ultimately aiming to improve outcomes for patients in Singapore.

1 of 1

Story summary

A groundbreaking study in Blood reveals that ADAR1 plays a crucial role in lenalidomide resistance in multiple myeloma. Lowering ADAR1 levels could boost treatment sensitivity, paving the way for innovative therapies like CRBN E3 ligase modulators and ADAR1 inhibitors, ultimately aiming to improve outcomes for patients in Singapore.